Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data. / Attauabi, Mohamed; Dahlerup, Jens Frederik; Poulsen, Anja; Hansen, Malte Rosager; Verner-Andersen, Marianne Kajbæk; Eraslan, Sule; Prahm, August Pilegaard; Pedersen, Natalia; Larsen, Lone; Jess, Tine; Neumann, Anders; Haderslev, Kent V; Molazahi, Akbar; Lødrup, Anders Berg; Glerup, Henning; Oppfeldt, Asser Mathiassen; Jensen, Michael Dam; Theede, Klaus; Kiszka-Kanowitz, Marianne; Seidelin, Jakob Benedict; Burisch, Johan.
In: Journal of Crohn's and Colitis, Vol. 16, No. 5, 2022, p. 757–767.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data
AU - Attauabi, Mohamed
AU - Dahlerup, Jens Frederik
AU - Poulsen, Anja
AU - Hansen, Malte Rosager
AU - Verner-Andersen, Marianne Kajbæk
AU - Eraslan, Sule
AU - Prahm, August Pilegaard
AU - Pedersen, Natalia
AU - Larsen, Lone
AU - Jess, Tine
AU - Neumann, Anders
AU - Haderslev, Kent V
AU - Molazahi, Akbar
AU - Lødrup, Anders Berg
AU - Glerup, Henning
AU - Oppfeldt, Asser Mathiassen
AU - Jensen, Michael Dam
AU - Theede, Klaus
AU - Kiszka-Kanowitz, Marianne
AU - Seidelin, Jakob Benedict
AU - Burisch, Johan
N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2022
Y1 - 2022
N2 - BACKGROUND AND AIMS: The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.
AB - BACKGROUND AND AIMS: The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.
U2 - 10.1093/ecco-jcc/jjab192
DO - 10.1093/ecco-jcc/jjab192
M3 - Journal article
C2 - 34755858
VL - 16
SP - 757
EP - 767
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
SN - 1873-9946
IS - 5
ER -
ID: 292162897